This real-world study, conducted in 13 different institutions across Spain confirms the unprecedented activity demonstrated by avapritinib in the NAVIGATOR clinical trial, which led to the regulatory approval of this agent in PDGFRA D842V-mutant GIST. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.